TSHA-101
Phase 1/2Active 1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infantile GM2 Gangliosidosis (Disorder)
Conditions
Infantile GM2 Gangliosidosis (Disorder)
Trial Timeline
Mar 12, 2021 → Mar 12, 2027
NCT ID
NCT04798235About TSHA-101
TSHA-101 is a phase 1/2 stage product being developed by Taysha Gene Therapies for Infantile GM2 Gangliosidosis (Disorder). The current trial status is active. This product is registered under clinical trial identifier NCT04798235. Target conditions include Infantile GM2 Gangliosidosis (Disorder).
What happened to similar drugs?
3 of 7 similar drugs in Infantile GM2 Gangliosidosis (Disorder) were approved
Approved (3) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
9
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04798235 | Phase 1/2 | Active |
Competing Products
16 competing products in Infantile GM2 Gangliosidosis (Disorder)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MAS825 + Placebo | Novartis | Phase 2 | 39 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 35 |
| Myozyme | Sanofi | Phase 2 | 35 |
| Bacillus Clausii Multi ATB Resist + Placebo | Sanofi | Approved | 43 |
| Radiprodil | UCB | Phase 2 | 27 |
| Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care | Bayer | Pre-clinical | 23 |
| Sabril® | Lundbeck | Pre-clinical | 23 |
| Vigabatrin | Lundbeck | Approved | 32 |
| Nusinersen | Biogen | Pre-clinical | 23 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 37 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 37 |
| Cerliponase Alfa | BioMarin Pharmaceutical | Pre-clinical | 27 |
| Cholic Acids | Mirum Pharmaceuticals | Phase 3 | 37 |
| Cipaglucosidase alfa + Miglustat | Amicus Therapeutics | Phase 3 | 44 |
| ATB200 + AT2221 | Amicus Therapeutics | Pre-clinical | 27 |
| RP-L401 | Rocket Pharmaceuticals | Phase 1 | 11 |